HKU Scholars Hub: Browsing DSpace

Browsing by Author Untch, M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 7 of 7

	Title	Author(s)	Issue Date	Views
	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Journal:The Lancet	Goldhirsch, A Gelber, RD Piccart-Gebhart, MJ de Azambuja, E Procter, M Suter, TM Jackisch, C Cameron, D Weber, HA Heinzmann, D Lago, LD McFadden, E Dowsett, M Untch, M Gianni, L Bell, R Köhne, CH Vindevoghel, A Andersson, M Brunt, AM Otero-Reyes, D Song, S Smith, I Leyland-Jones, B Baselga, J Kwong, A	2013	10
	Estimating The Magnitude Of Trastuzumab Effects Within Patient Subgroups In The Hera Trial Journal:Annals of Oncology	Untch, M Gelber, RD Jackisch, C Procter, M Baselga, J Bell, R Cameron, D Bari, M Smith, I Leyland-Jones, B de Azambuja, E Wermuth, P Khasanov, R Feng-yi, F Constantin, C Mayordomo, JI Su, CH Yu, SY Lluch, A Senkus-Konefka, E Price, C Haslbauer, F Sahui, TS Srimuninnimit, V Colleoni, M Coates, AS Piccart-Gebhart, MJ Goldhirsch, A Kwong, A	2008	68
	Event-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522 Journal:Annals of Oncology	Pusztai, L Denkert, C O’Shaughnessy, J Cortes, J Dent, R McArthur, H Kummel, S Bergh, J Park, YH Hui, R Harbeck, N Takahashi, M Untch, M Fasching, PA Cardoso, F Zhu, Y Pan, W Tryfonidis, K Schmid, P	16-Feb-2024
	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Journal:Lancet	Baselga, J Bradbury, I Eidtmann, H Di Cosimo, S de Azambuja, E Aura, C Gomez, H Dinh, P Fauria, K Van Dooren, V Aktan, G Goldhirsch, A Chang, TW Horvath, Z Coccia-Portugal, M Domont, J Tseng, LM Kunz, G Sohn, JH Semiglazov, V Lerzo, G Palacova, M Probachai, V Pusztai, L Untch, M Gelber, RD Piccart-Gebhart, M NeoALTTO Study Team,Kwong, A	2012	190
	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Journal:New England Journal of Medicine	Piccart-Gebhart, MJ Procter, M Leyland-Jones, B Goldhirsch, A Untch, M Smith, I Gianni, L Baselga, J Bell, R Jackisch, C Cameron, D Dowsett, M Barrios, CH Steger, G Huang, CS Andersson, M Inbar, M Lichinitser, M Láng, I Nitz, U Iwata, H Thomssen, C Lohrisch, C Suter, TM Rüschoff, J Sütő, T Greatorex, V Ward, C Straehle, C McFadden, E Dolci, S Gelber, RD Herceptin Adjuvant (HERA) Trial Study Team Kwong, A	2005
	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Journal:New England Journal of Medicine	von Minckwitz, G Huang, CS Mano, MS Loibl, S Mamounas, EP Untch, M Wolmark, N Rastogi, P Schneeweiss, A Redondo, A Fischer, HH Jacot, W Conlin, AK Arce-Salinas, C Wapnir, IL Jackisch, C DiGiovanna, MP Fasching, PA Crown, JP Wülfing, P Shao, Z Rota Caremoli, E Wu, H Lam, LH Tesarowski, D Smitt, M Douthwaite, H Singel, SM Geyer, CE The KATHERINE Investigators Kwong, A	2019
	Treatment With Trastuzumab For 1 Year After Adjuvant Chemotherapy In Patients With Her2-positive Early Breast Cancer: A 4-year Follow-up Of A Randomised Controlled Trial Journal:The Lancet Oncology	Gianni, L Dafni, U Gelber, RD Azambuja, E Muehlbauer, S Goldhirsch, A Untch, M Smith, I Baselga, J Jackisch, C Cameron, D Mano, M Pedrini, JL Veronesi, A Mendiola, C Pluzanska, A Semiglazov, V Vrdoljak, E Eckart, MJ Shen, Z Skiadopoulos, G Procter, M Pritchard, KI Piccart-Gebhart, MJ Bell, R Kwong, A	2011	9

Showing results 1 to 7 of 7